- The round is led by Capital Cell with a €500K ticket and it is completed with a €1M loan from Banco Santander
- The investment will be allocated to accelerate the launching of a solution to pre-diagnose idiopathic pulmonary fibrosis (IPF) and murmurs in pediatric cardiology
- The project is supported by the pharmaceutical company Boehringer Ingelheim and the Health Research Institute La Fe
The Valencian company eKuore opens a €500,000 round of investment through the Capital Cell platform to complete a round of €1.5M, as it already had secured another million euros with a loan granted by ‘Fondo Smart’, Banco Santander. The fund raising campaign, which has special conditions during the first two weeks of the launch, is open to all type of investor, as the minimum contribution is €100.
eKuore’s value propositon is based on creating a system that enables the early detection of idiopathic pulmonary fibrosis (IPF) and murmurs in pediatric cardiology, using an algorithm to recognise auscultation results obtained with the company’s digital stethoscope.
Rubén López, CEO of eKuore, states that ‘what this company wants with this investment round is to accelerate the project in order to launch onto the market a pre-diagnosis system that enables the doctor to recognise a disease up to two years earlier than with current processes’.
Today, there are pathologies with a high mortality rate, such as idiopathic pulmonary fibrosis (IPF) in pneumology, which are very difficult to diagnose by health professionals using current methods, specially in the early stages, since the symptoms are often confused with those caused by other common diseases, such as asthma or COPD. At the same time, in pediatric cardiology, a high percentage of patients are unnecessarily referred to the specialist due to innocent murmurs (by definition, an innocent murmur is non-pathological and therefore usually does not need treatment of any kind), which results in the saturation of the system and a higher cost.
eKuore is already a consolidated company in the development of diagnostic hardware devices, and has four different ranges of digital stethoscopes for both humans and animals. The products have obtained the European CE Marking and the American FDA clearance. The company currently distributes in more than 30 countries and has had a turnover of more than €2.5 million since it was founded in 2013.
In 2013, it was backed by Lanzadera, the accelerator belonging to Marina de Empresas and promoted by Juan Roig. On the other hand, since 2016, it has collaborated with Boehringer Ingelheim, a multinational pharmaceutical company, to develop a solution that enables pre-diagnosis
Do you want to part of the project? ->Go to the funding round
